Type II congenital dyserythropoietic anaemia (CDA-II or HEMPAS) is an autosomal recessive disorder, representing the most frequent form of congenital dyserythropoiesis. It is characterised by normocytic anaemia, variable jaundice and hepato-splenomegaly. Gallbladder disease and secondary haemochromatosis are frequent complications. We report a case characterised by severe transfusion-dependent anaemia. The proband inherited CDA-II in association with beta-thalassaemia trait. Splenectomy did not abolish the transfusion dependence and this, in association with poor compliance to iron-chelation therapy, prompted us to consider bone marrow transplantation (BMT) from his HLA-identical sibling. The preparative regimen included busulfan, thiotepa and fludarabine, and graftversus-host disease prophylaxis consisted of cyclosporin A and short-term methotrexate. Engraftment of donor cells was prompt and the post-transplant course uncomplicated. The patient is alive and transfusion-independent 36 months after allograft. This is the first case of severe CDA-II to undergo BMT. Analysis of this pedigree suggests that interaction with beta-thalassaemia enhanced the clinical severity of CDA-II, making BMT an attractive therapy for patients with transfusion dependence. Bone Marrow Transplantation (2001) 27, 213-215.
peripheral cisternae running parallel to and beneath the plasma membrane.
1,2 Recently, we obtained conclusive evidence for linkage of CDA II to microsatellite markers on the long arm of chromosome 20 (20q11.2). 3, 4 Strong evidence of allelic association with the disease was also detected with marker D20S863. Localisation of the gene allowed molecular studies, revealing the presence of genetic heterogeneity which seems to account for 10% of CDA-II cases. 5 Clinical manifestations of the vast majority of patients with CDA-II are mild. During the neonatal period, very few children require phototherapy or erythrocyte transfusions (unpublished observations). Gallbladder disease and secondary haemochromatosis are frequent late complications. 6 We report a patient with transfusion-dependent congenital CDA-II associated with beta-thalassaemia trait, who was successfully treated with allogeneic bone marrow transplantation (BMT) from his HLA-identical sibling.
Clinical report
The family came from southern Italy and consisted of three children: two of them (II-1 and II-2) affected by CDA-II (see also Table 1 for further details). The mother and one child (I-2 and II-2) had beta-thalassaemic traits.
In the patients II-1 and II-2, anaemia has been documented since the newborn period, when jaundice required Table 1 Clinical and molecular data exchange transfusion. Bone marrow appearances, as well as SDS-PAGE and Western blotting of RBC cytoskeleton proteins, showed the characteristic pattern of CDA-II. During infancy and childhood, both patients received erythrocyte transfusions. In one patient (II-1) splenectomy abolished the transfusion requirement, whereas it did not produce any benefit in the other CDA-II proband (II-2). Patient II-1 developed chronic hepatitis due to HCV infection, which, in association with cardiac failure secondary to iron overload, caused his death at the age of 15.
Since patient II-2 had transfusion dependence and poor compliance with iron chelation therapy, the parents asked us to consider allogeneic BMT from his HLA-compatible sibling. At time of transplantation, his ferritin serum value was 3500 ng/ml.
Conditioning comprised busulfan (16 mg/kg in 16 divided doses) from day −10 to day −7, thiotepa (3 mg/kg/12 h) on day −6, and fludarabine (40 mg/m 2 /day) i.v. from day −5 to day −2. The number of nucleated cells infused was 5.85 × 10 8 /kg of recipient body weight. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporin A and short-term methotrexate. 7 Haematopoietic and lymphoid engraftment were documented by studying the genetic polymorphism of variable number of tandem repeat short DNA sequences (VNTRs). 8 Engraftment of donor cells was prompt and the posttransplant course uncomplicated. The child recovered an absolute neutrophil count greater than 0.5 × 10 9 /l on day +14 after transplantation, whereas platelet engraftment (у20 × 10 9 /l) was observed on day +21. Details on sequential red cell indices, reticulocyte counts, ferritin levels and donor chimerism are reported in Table 2 .
Thirty-six months after BMT, the patient is alive with normal Hb levels and is not receiving any immune suppressive therapy. A program of periodic phlebotomy with the aim of removing excess iron has been started, the last ferritin serum value being 1180 ng/ml.
Discussion
To our knowledge, this is the first case of CDA-II treated with allogeneic BMT. Generally speaking, CDA-II does not cause transfusion dependence. We found five cases of transfusion dependence in the International Registry of CDA-II (unpublished data). Three of these are characterised by interaction of CDA-II with beta thalassaemia trait. Three cases were not in linkage with chromosome 20.
These data may suggest that the severe clinical picture of this transfusion-dependent CDA-II patient was due to either a different gene located outside chromosome 20 or to a detrimental, synergistic effect played by the association of the dyserythropoiesis with beta-thalassaemia, a red cell defect, which, per se, causes dyserythropoiesis.
Linkage analysis by means of microsatellite markers localised on the long arm of chromosome 20 performed in these families demonstrated that the CDA-II locus was not linked to chromosome 20 (see also Table 1 ). As a matter of fact, there is no segregation of alleles of each marker with the disease.
Since our patient with CDA-II (II-2) and beta-thalassaemia trait failed to benefit from splenectomy, whereas this procedure had a favourable effect in the proband (II-1) without beta-thalassaemia trait, it is likely that interaction between these two conditions was responsible for the more severe clinical picture. In fact, excess of globin alphachains with precipitation within CDA-II erythroid cells, may contribute to increase ineffective erythropoiesis.
Allogeneic BMT from an HLA-identical sibling cured this patient with CDA-II and beta-thalassaemia trait. This treatment can abolish transfusion dependence in patients with erythroid disorders, 9 thus preventing progression of the tissue damage related to iron overload, which can also occur in CDA-II patients without beta-thalassaemia trait. The result should be both longer life expectancy and better quality of life.
Since we were worried about the iron accumulated before transplantation in patient II-2, we decided to use fludarabine instead of cyclophosphamide in the preparative regimen. In fact, fludarabine displays a potent immunosuppressive effect and has been used successfully in allogeneic transplantation of haematopoietic stem cells. [10] [11] [12] [13] Terenzi and colleagues 14 have documented that fludarabine can replace cyclophosphamide in pre-transplant conditioning therapy. Moreover, previous studies have shown that fludarabine-based preparative regimens are well tolerated, have limited extra-medullary toxicity and are currently used in patients who are not eligible for conventional myeloablative conditioning because of advanced age and/or poor performance status. [10] [11] [12] [13] 15 
